Physician profile
Bruce C Rowe
NPI 1689732422
$1,329.05
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $337 · 2021: $254 · 2022: $14.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.79 | 2019-2022 | |
| Astellas Pharma US INC | $224.36 | 2019-2021 | |
| Boston Scientific Corporation | $168.48 | 2019 | |
| Dendreon Pharmaceuticals LLC | $136.96 | 2019-2020 | |
| Novo Nordisk INC | $111.71 | 2019 | |
| Allergan, INC. | $104.81 | 2019-2020 | |
| Coloplast Corp | $58.95 | 2019 | |
| Rochester Medical Corporation | $43.77 | 2019 | |
| Neotract INC. | $39.25 | 2020 | |
| Axonics, INC. | $25.99 | 2020 | |
| Photocure INC | $17.01 | 2019 | |
| Abbvie INC. | $15.42 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $14.75 | 2019 | |
| Baudax Bio INC. | $13.82 | 2020 | |
| Therapeuticsmd, INC. | $13.52 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13.46 | 2019 | |
| Endo Pharmaceuticals INC. | $11.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.20 | 2019 | |
| Zyla Life Sciences, INC. | $11.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.